DIabète / Diabetes pompe à insuline et le smartphone afin d'ajuster data to the patient. Treatment satisfaction with automatiquement et en temps réel le dosage de CGM is receiving growing attention as more l'insuline en fonction de l'évolution de la glycémie. people with diabetes adopt the technology to Le mois suivant, la FDA a approuvé un lecteur control and manage their condition. As a result, autonome pour FreeStyle Libre 3. Le lecteur the worldwide CGM device market was valued est un petit appareil portable qui affiche les at $6.83 billion in 2022 and is expected to reach mesures de glucose en temps réel directement à $16.33 billion by 2030.14 partir d'un petit capteur situé à l'arrière du bras. Dans l'ensemble, les ventes de FreeStyle Libre au Abbott Laboratories and DexCom, Inc. are two troisième trimestre 2023 ont fait un bond de of the leading device CGM manufacturers vying 30,5 % pour atteindre 1,4 milliard de dollars (16) for their share of this growing market. Abbott’s . FreeStyle Libre portfolio is currently being used DexCom a vu ses ventes augmenter au troisième by 5 million people across 62 countries.15 The trimestre pour atteindre 975 millions de dollars et a portfolio includes: FreeStyle Libre 14 day, a CGM relevé ses prévisions de recettes annuelles à that includes the LibreLink app and a glucose 3,6 milliards de dollars en raison de la forte demande sensor worn on the back of the arm for 14 days pour ses dispositifs CGM . Cela s'explique par(17) to measure glucose levels every minute; FreeStyle l'annonce récente de la connexion de son CGM G7 Libre 2 is integrated CGM that continuously avec la pompe à insuline t:slim X2TM de Tanden transmits glucose data every minute to alert Diabetes Care aux États-Unis et sur de nombreux users when their glucose is high or low; and most marchés en Europe et en Asie-Pacifique, dont les recently, FreeStyle Libre 3, a 14-day CGM that recettes devraient s'accélérer en 2024. Il s'agit de la sends readings to a smartphone every minute. In première intégration d'un système d'administration March 2023, the FDA cleared Libre 2 and 3 for automatisée d'insuline (AID) avec G7. Le CGM integration with automated insulin delivery (AID) s'intègre désormais également aux pompes à insuline systems, which connect the CGM, insulin pump iLet et utilise des algorithmes intelligents pour and smartphone to automatically adjust insulin ajuster automatiquement l'administration d'insuline. dosing in real-time in response to changing Cependant, les rapports sur les revenus montrent que glucose levels. The following month, the FDA les actions de DexCom ont chuté de 16 % en 2023 approved a stand-alone reader for FreeStyle Libre (18), principalement en raison des inquiétudes que 3. The reader is a small handheld device that les nouveaux médicaments contre le diabète à displays real-time glucose readings directly from base de glucagon-like peptide-1 (GLP-1), tels que a small sensor on the back of the upper arm. l'Ozempic de Novo Nordisk et le Mounjaro d'Eli Overall, third-quarter 2023 sales of FreeStyle Lilly, pourraient absorber les ventes des appareils Libre jumped 30.5% to $1.4 billion.16 CGM. DexCom saw Q3 sales rise to $975 million and raised its annual revenue forecast to $3.6 billion CGMs AND AID INTEGRATION based on strong demand for its CGM devices.17 This comes with the recent announcement that The National Institutes of Health Standard of its G7 CGM now connects with the t:slim X2TM Care recommends continuous glucose monitoring insulin pump by Tanden Diabetes Care in the (CGM) to manage Type 1 diabetes (T1D), but U.S. and multiple markets across Europe and there has been a hard push to extend its use to Asia-Pacific, revenue is expected to accelerate Type 2 diabetes (T2D). Research presented at the in 2024. This marked the first automated European Association for the Study of Diabetes insulin delivery (AID) system integration with annual meeting in Germany this past October G7. The CGM now also integrates with iLet indicates that the devices are adapting to this insulin pumps and uses smart algorithms to evolution. A CGM includes a small electrode automatically adjust insulin delivery. But revenue placed beneath the skin, a transmitter that sends reports show DexCom’s shares dropped 16% readings at regular intervals, and a receiver. in 2023,18 mainly based on concerns that new The enzymatic technology used by currently glucagon-like peptide-1 (GLP-1) diabetes drugs approved CGMs reacts with glucose molecules such as Novo Nordisk’s Ozempic and Eli Lilly's in the interstitial fluid to generate an electric Mounjaro could eat into the sales of CGM current, which is then relayed from a transmitter devices. attached to a sensor, and in turn displays the 34The Pharmaceutical Post 17 / Janvier - 2024